These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30885996)

  • 1. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
    Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ; Deininger M
    J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
    Barber MC; Mauro MJ; Moslehi J
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
    Gurion R; Raanani P; Vidal L; Leader A; Gafter-Gvili A
    Acta Oncol; 2016; 55(9-10):1077-1083. PubMed ID: 27560448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
    Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
    Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension in patients with chronic myeloid leukemia.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
    Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
    Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
    Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.